PT-141 for Female Sexual Interest: Vyleesi Approval and Real-World Data
From Sunless Tanning to Sexual Medicine
The journey of PT-141 (bremelanotide) from a failed tanning peptide to an FDA-approved treatment for hypoactive sexual desire disorder (HSDD) is one of the more unusual stories in pharmaceutical development. Originally derived from Melanotan II, a synthetic melanocortin analog studied for UV-free tanning, researchers noticed an unexpected side effect during early trials — participants reported significant increases in sexual arousal.
This serendipitous finding redirected the molecule's development entirely. Unlike other HSDD treatments that act on serotonin pathways, bremelanotide works through the melanocortin system, targeting receptors in the central nervous system that modulate sexual desire. In June 2019, the FDA approved bremelanotide under the brand name Vyleesi (AMAG Pharmaceuticals), making it only the second drug ever approved for premenopausal HSDD — and the first to work through an entirely novel mechanism.
Mechanism of Action
Bremelanotide is a cyclic heptapeptide that acts as a nonselective agonist at melanocortin receptors, with particular affinity for the melanocortin-4 receptor (MC4R). These receptors are expressed in brain regions involved in sexual behavior, including the hypothalamus and limbic system. Kingsberg et al., 2019 described how MC4R activation in these areas modulates dopaminergic and oxytocinergic pathways implicated in sexual motivation and arousal.
Unlike flibanserin (Addyi), which requires daily oral dosing and acts as a 5-HT1A agonist / 5-HT2A antagonist, bremelanotide is administered subcutaneously on an as-needed basis at least 45 minutes before anticipated sexual activity. This on-demand dosing model more closely mirrors how patients experience desire and represents a fundamentally different treatment paradigm.
The distinction matters pharmacologically. Flibanserin requires weeks of daily dosing to achieve its effect through gradual serotonergic rebalancing. Bremelanotide produces a more acute response, with peak plasma concentrations reached approximately 1 hour after subcutaneous injection and an elimination half-life of roughly 2.7 hours (FDA Label, 2019).
Pivotal Clinical Trials
The FDA approval was based primarily on two Phase 3 randomized, double-blind, placebo-controlled trials: RECONNECT Study 1 and Study 2, which enrolled over 1,200 premenopausal women diagnosed with HSDD. These trials were published by Kingsberg et al., 2019 in the New England Journal of Medicine.
Key findings from the RECONNECT program include:
The clinical significance of these improvements has been debated. Jaspers et al., 2016 had previously raised concerns about the modest effect sizes observed across HSDD drug trials, and similar criticisms were applied to bremelanotide. Approximately 25% of bremelanotide-treated patients reported meaningful improvement in desire versus 17% in the placebo group.
Safety Profile and Tolerability
Tolerability emerged as a notable concern during clinical development. The most common adverse effect was nausea, reported by approximately 40% of patients in the pivotal trials, compared to around 1% in placebo groups (Clayton et al., 2016). While nausea was generally mild to moderate and tended to decrease with repeated use, it led to treatment discontinuation in a meaningful subset of participants.
Other reported adverse events included:
The blood pressure finding prompted a boxed warning against use in patients with uncontrolled hypertension or cardiovascular disease. The FDA also limited the approved dosing frequency to no more than one 1.75 mg injection per 24 hours and no more than 8 doses per month due to the blood pressure signal.
An earlier intranasal formulation was abandoned after Phase 3 trials revealed more pronounced blood pressure increases, as detailed by Diamond et al., 2006. The subcutaneous route provided a more favorable hemodynamic profile.
Real-World Data and Post-Market Experience
Post-approval real-world data has painted a mixed picture. Commercial uptake of Vyleesi has been modest, influenced by several factors including the need for subcutaneous self-injection, high out-of-pocket costs (frequently exceeding $800 per month without insurance coverage), and the nausea burden.
A real-world analysis by Krop et al., 2022 examining pharmacy claims data found that persistence rates were low, with a majority of patients not refilling prescriptions beyond the first or second month. Among those who continued treatment beyond 3 months, however, satisfaction scores were notably higher, suggesting a self-selecting population of strong responders.
Portman et al., 2023 published open-label extension data showing that long-term use (up to ~15 months) did not reveal new safety signals, and patients who remained on therapy reported sustained improvements in desire and reductions in distress. The nausea rate declined to approximately 22% among patients with continued exposure, suggesting some degree of tachyphylaxis to this side effect.
Patient-reported experience data from the clinical program also revealed qualitative improvements beyond what numerical scores captured. Women described the change not simply as increased libido but as a restoration of receptivity to sexual cues — a nuanced distinction that standard clinical endpoints may inadequately measure.
Comparison With Other Approaches
For premenopausal HSDD, the current pharmacological landscape includes:
A systematic review by Gao et al., 2022 comparing pharmacological interventions for HSDD found broadly similar efficacy between flibanserin and bremelanotide, with differences primarily in route, timing, and side effect profiles rather than overall effectiveness. The choice between them often comes down to patient preference regarding dosing convenience versus tolerability tradeoffs.
Ongoing Research and Unanswered Questions
Several questions remain active areas of investigation. Researchers continue to explore whether melanocortin-based therapies might benefit postmenopausal women, a population excluded from the pivotal trials. Early-phase research also examines potential applications in male sexual dysfunction, building on earlier studies by Safarinejad, 2008 that showed bremelanotide improved erectile function in men with erectile dysfunction.
There is also growing interest in understanding why some women respond dramatically while others experience minimal benefit. Genetic polymorphisms in the MC4R gene, baseline hormonal profiles, and psychological factors may all contribute to this variability. Identifying reliable biomarkers for treatment response could transform how bremelanotide is prescribed.
The broader melanocortin field continues to advance, with novel selective MC4R agonists in early development that may offer improved side effect profiles by avoiding activation of MC1R (skin pigmentation) and MC3R.